
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Tarsus Pharmaceuticals Inc (TARS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)

(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: TARS (4-star) is a STRONG-BUY. BUY since 48 days. Simulated Profits (56.64%). Updated daily EoD!
1 Year Target Price $78.38
1 Year Target Price $78.38
6 | Strong Buy |
1 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 295.29% | Avg. Invested days 49 | Today’s Advisory Strong Buy |
Upturn Star Rating ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() | ![]() |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.16B USD | Price to earnings Ratio - | 1Y Target Price 78.38 |
Price to earnings Ratio - | 1Y Target Price 78.38 | ||
Volume (30-day avg) 8 | Beta 0.81 | 52 Weeks Range 35.84 - 76.81 | Updated Date 10/17/2025 |
52 Weeks Range 35.84 - 76.81 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -31.13% | Operating Margin (TTM) -21.61% |
Management Effectiveness
Return on Assets (TTM) -14.06% | Return on Equity (TTM) -31.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2172226009 | Price to Sales(TTM) 10.71 |
Enterprise Value 2172226009 | Price to Sales(TTM) 10.71 | ||
Enterprise Value to Revenue 7.35 | Enterprise Value to EBITDA -3.23 | Shares Outstanding 42214106 | Shares Floating 30387402 |
Shares Outstanding 42214106 | Shares Floating 30387402 | ||
Percent Insiders 3.18 | Percent Institutions 114.44 |
Upturn AI SWOT
Tarsus Pharmaceuticals Inc

Company Overview
History and Background
Tarsus Pharmaceuticals, Inc. was founded in 2016 and is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing novel therapeutics to address unmet needs. Their initial focus has been on eye care. Tarsus Pharmaceuticals is located in Irvine, California.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and commercialization of new pharmaceutical products, particularly in eye care. Specializes in the treatment of Demodex blepharitis. Developing treatments in other areas like Meibomian gland dysfunction (MGD).
Leadership and Structure
Dr. Bobak Azamian is the Chairman and CEO. The company has a management team with experience in pharmaceutical development and commercialization. The company structure is typical of a biotech firm, including research and development, clinical operations, commercial strategy, and financial management.
Top Products and Market Share
Key Offerings
- XDEMVY (lotilaner ophthalmic solution) 0.25%: XDEMVY is FDA-approved for the treatment of Demodex blepharitis. Tarsus has launched XDEMVY into the market and is currently working on expanding its reach. Tarsus estimates that roughly 25 million people in the US have Demodex blepharitis. Tarsus expects the Demodex blepharitis market to be approximately $1 billion. Key competitors would be off-label treatments and compounded products, and Bausch & Lomb (BLCO) and other major ophthalmic players may introduce their own prescription treatments in the future.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly in eye care, is competitive and growing. There is significant demand for treatments for conditions like Demodex blepharitis. Development and regulatory processes are complex and time-consuming.
Positioning
Tarsus Pharmaceuticals is positioned as an innovative company focused on addressing underserved needs in eye care. They are the first to have an FDA-approved product for Demodex blepharitis.
Total Addressable Market (TAM)
The market for Demodex blepharitis treatment is estimated to be approximately $1 billion. Tarsus, with the approval of XDEMVY, is well-positioned to capture a significant portion of this market, particularly as the first FDA-approved therapy.
Upturn SWOT Analysis
Strengths
- First FDA-approved treatment for Demodex blepharitis
- Strong intellectual property protection
- Experienced management team focused on eye care
- Strong clinical trial results for XDEMVY
Weaknesses
- Reliance on a single product (XDEMVY)
- Limited commercial history as a relatively new company
- Potential for competition from larger pharmaceutical companies
- Manufacturing and supply chain dependencies
Opportunities
- Expansion of XDEMVY into additional markets
- Development of new therapies for other eye conditions
- Partnerships with larger pharmaceutical companies
- Increased awareness of Demodex blepharitis
Threats
- Competition from generic or biosimilar products
- Unfavorable regulatory changes
- Failure to gain market acceptance for XDEMVY
- Product liability claims
Competitors and Market Share
Key Competitors
Competitive Landscape
Tarsus Pharmaceuticals is the first to market with an FDA-approved treatment for Demodex blepharitis, giving it a competitive advantage. However, larger pharmaceutical companies may enter the market with competing products in the future. Tarsus Pharmaceuticals competes with Allergan (ABBV) and Bausch & Lomb (BLCO) in the eye care market.
Growth Trajectory and Initiatives
Historical Growth: Tarsus Pharmaceuticals is a young company with limited historical financial data available. Most of their growth trajectory is projected.
Future Projections: Analysts project significant revenue growth for Tarsus based on the launch of XDEMVY and potential expansion into other markets.
Recent Initiatives: Successful FDA approval and commercial launch of XDEMVY. Continued clinical development of additional eye care products.
Summary
Tarsus Pharmaceuticals is a promising biopharmaceutical company that is looking to continue innovating in the treatment of eye care conditions. With the FDA approval of XDEMVY, the company is positioned for significant growth. However, its reliance on a single product makes it vulnerable to competition and regulatory changes. Tarsus Pharmaceuticals needs to diversify its product pipeline and ensure successful commercialization of XDEMVY to sustain its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tarsus Pharmaceuticals Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tarsus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2020-10-16 | Co-Founder, President, CEO & Chairman Dr. Bobak R. Azamian M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 323 | Website https://www.tarsusrx.com |
Full time employees 323 | Website https://www.tarsusrx.com |
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.